RETRACTED: Transferrin-Conjugated Chitosan Nanoparticles for Direct Nose-to-Brain Delivery of Ziprasidone: Pharmacokinetic and Pharmacodynamic Evaluation
Molecular Pharmaceutics · 2025
DOI: 10.1021/acs.molpharmaceut.5c00863 ↗Kurz gefasst
Fachartikel in der Zeitschrift Molecular Pharmaceutics, 2025. Verfasst von Teja Kumar Ponduri und 4 weiteren Autor:innen. Beteiligte Einrichtung: KL College of Pharmacy, Koneru Lakshmaiah Education Foundation, Vaddeswaram, Andhra Pradesh 522302, India. Hauptthemen laut MEDLINE: Piperazines, Nanoparticles, Transferrin, Brain. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 73 Literaturangaben.
Abstract (Originalsprache)
Ziprasidone (ZS) exhibits limited central nervous system (CNS) penetration due to the blood–brain barrier (BBB). This study investigated the pharmacokinetics and pharmacodynamics of ZS-loaded nanoparticles (NP) and transferrin-functionalized nanoparticles (Tf-NP) administered intravenously (IV) and intranasally (IN) in rats. Brain and plasma concentrations were quantified up to 24 h, and parameters including Cmax, AUC0–24, brain-to-plasma ratios, drug targeting efficiency (%DTE), and direct transport percentage (%DTP) were assessed. Behavioral assays evaluated antipsychotic efficacy. IN administration of NP and Tf-NP significantly enhanced brain exposure relative to IV and IN drug solution, with Tf-NP achieving the highest brain Cmax (329.17 ± 19.79 ng/mL) and AUC0–24 (4004.73 ± 396.87 ng·h/mL), and a %DTP exceeding 92%, indicative of effective nose-to-brain bypass of the BBB. Plasma exposure was reduced for NP and Tf-NP versus IV (Cmax and AUC0–∞), minimizing systemic side effects. Brain-to-plasma ratios markedly increased for NP (1.31) and Tf-NP (1.50) compared to IV (0.13). Tf-NP also elicited a faster onset and sustained pharmacodynamic response. These data demonstrate that intranasal Tf-functionalized ZS nanoparticles significantly improve CNS targeting and bioavailability while mitigating systemic exposure, supporting their development as targeted therapeutics for neuropsychiatric disorders.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- KL College of Pharmacy, Koneru Lakshmaiah Education Foundation, Vaddeswaram, Andhra Pradesh 522302, India.
- Department of Pharmaceutics, Nova College of Pharmaceutical education and Research, JNTU Kakinada, Kakinada, Andhra Pradesh 521456, India.
ORCID-Profile: Teja Kumar Ponduri
Zitieren
APA
Ponduri, T. K., Guntupalli, C., Jeganathan, B., Malothu, N., & Kowtharapu, S. (2025). RETRACTED: Transferrin-Conjugated Chitosan Nanoparticles for Direct Nose-to-Brain Delivery of Ziprasidone: Pharmacokinetic and Pharmacodynamic Evaluation. Molecular Pharmaceutics. https://doi.org/10.1021/acs.molpharmaceut.5c00863
Vancouver
Ponduri TK, Guntupalli C, Jeganathan B, Malothu N, Kowtharapu S. RETRACTED: Transferrin-Conjugated Chitosan Nanoparticles for Direct Nose-to-Brain Delivery of Ziprasidone: Pharmacokinetic and Pharmacodynamic Evaluation. Molecular Pharmaceutics. 2025. doi:10.1021/acs.molpharmaceut.5c00863
BibTeX
@article{Ponduri2025,
author = {Ponduri, Teja Kumar and Guntupalli, Chakravarthi and Jeganathan, Balamurugan and Malothu, Narender and Kowtharapu, Swetha},
title = {RETRACTED: Transferrin-Conjugated Chitosan Nanoparticles for Direct Nose-to-Brain Delivery of Ziprasidone: Pharmacokinetic and Pharmacodynamic Evaluation},
journal = {Molecular Pharmaceutics},
year = {2025},
doi = {10.1021/acs.molpharmaceut.5c00863}
}
EUVIMED